SGLT2 Inhibitor Utilization Re-perfusion Therapy

Launched by TAICHUNG VETERANS GENERAL HOSPITAL · Mar 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the potential benefits of a medication called Canagliflozin, an SGLT2 inhibitor, for patients who have suffered an acute ischemic stroke due to a blockage in a large blood vessel. The main goal is to see if Canagliflozin can help reduce complications after treatment, specifically the risk of bleeding in the brain and swelling that can worsen the patient's condition. Participants in the study will be randomly assigned to either take Canagliflozin daily for 14 days or receive no additional treatment before undergoing a procedure called mechanical thrombectomy to remove the blockage.

To qualify for the trial, participants need to be adults who have been diagnosed with an acute ischemic stroke and are scheduled for the thrombectomy procedure. However, those with severe kidney problems, certain allergies, or specific health conditions like type 1 diabetes will not be eligible. Participants will have their health closely monitored, with assessments of their stroke severity and recovery at various points, including after the procedure and three months later. This research could potentially lead to new treatment options that improve recovery for stroke patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients must have been diagnosed with acute ischemic stroke and large vessel occlusion by a neurologist, with confirmation supported by CT perfusion scans.
• • Patients must be scheduled to undergo mechanical thrombectomy.
• Exclusion Criteria:
• • Patients with have stage 4 or 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² on dialysis)
• • Patients with currently taking an SGLT2i or within 3 months prior to enrollment
• • Patients with a known hypersensitivity or allergic reaction to Canagliflozin
• • Patients with type 1 diabetes mellitus
• • Patients with pregnancy or lactation